New app improves cardiac remote monitoring workflows by providing clinicians access to Implicity alerts and reports directly within Epic’s electronic medical records systems. CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ — Implicity®, a leader in remote patient monitoring (RPM) and cardiac data management solutions, released a new SMART on FHIR application to improve interoperability and […]
Author: Ken Dropiewski
Lohman Technologies’ latest HomECG+ device promotes health equity with ease of use and embedded cellular technology
The latest version of the HomECG+ helps close the health equity gap by providing access to care for all patient types, including rural health, underserved populations, geographic disparities, and low-income populations. MILWAUKEE, March 2, 2023 /PRNewswire/ — Lohman Technologies recently announced the release of their 2.0, next-generation, HomECG+ product. The FDA-cleared, clinical-grade […]
Microbot Medical Leverages Recently Awarded Non-Dilutive Grant from the Israeli Government to Promote Marketing Activities Toward Commercialization of the LIBERTY® Robotic System
Engagement with Interventional Radiologists Reaches Highest Level Yet as Company Continues to Progress Through Regulatory and Clinical Phases; Company Seeking to Create Interest and Anticipation for When the System is Commercialized HINGHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., March 01, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on March 1, 2023 that were approved by the Compensation Committee of its Board of […]
Cytokinetics Reports Fourth Quarter 2022 Financial Results
Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company […]
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December […]
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporting Runway into the Second Half of 2025 BOSTON, March 02, 2023 […]
Investor Insights: Geoff Pardo – What is Your Typical Investment Size? (Part 3)
McDermott + Bull Partner Ken Dropiewski interviews Gilde Healthcare General Partner Geoff Pardo in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Geoff discuss what venture in MedTech will look like in 2023, what Gilde Healthcare looks for in new investment opportunities, and more.
SpectraWAVE Secures 510(k) Clearance of HyperVue™ Intravascular Imaging System
— System Leverages Next Generation DeepOCT™ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab — — First-in-Human Cases Completed with HyperVue System — BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery […]
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file INDi application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of […]



